LUCERNA trial explores novel gastric cancer therapy.
Analysis Emergency Medicine
Shitara K, Enzinger P, Lordick F, et al.
Aug 12, 2026 · Published in: ESMO Gastrointestinal Oncology
Exploring new frontiers: a trial for gastric cancer therapy.
Fluid Balance, Not Ultrafiltration Rate, Drives CRRT Mortality
Analysis Critical Care / ICU Hypothesis-generating Grade: Low
Monai NC, Pfortmueller CA, Schefold JC, et al.
Aug 12, 2026 · Published in: Critical Care Medicine
Fluid balance, not ultrafiltration rate, influences CRRT mortality.
Anti-TNF Falters After Prior Non-Anti-TNF Biologic, Especially in Ulcerative Colitis
Analysis Clinical Practice Hypothesis-generating Grade: Low
Yagüe Caballero C, García López S, Royo Esteban A, et al.
Aug 12, 2026 · Published in: Alimentary Pharmacology & Therapeutics
Anti-TNF therapy is less effective after biologics with different mechanisms.
Fresenius Kabi Recalls One Lot of Tyenne (tocilizumab-aazg) for Glass Particles
Analysis Medication Safety / Pharmacovigilance Practice-changing Grade: High
Aug 11, 2026 · Published in: FDA MedWatch
A critical recall of Tyenne due to glass particles.
International Expert Consensus Optimizes Asparaginase and Blinatumomab in Frontline ALL
Consensus Statement Oncology / Supportive Care Confirmatory Grade: Low
DeAngelo DJ, Avagyan A, Alfaro J, et al.
Aug 11, 2026 · Published in: Cancer
Expert consensus guides asparaginase and blinatumomab integration in leukemia treatment.
Adjunctive Bacteriophage Therapy for Malakoplakia Study
Analysis Infectious Disease / Antimicrobials
Aslam S, Brubaker A, Shah M, et al.
Aug 11, 2026 · Published in: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
First successful bacteriophage therapy for a transplant infection complication.
Tyenna Injection Recalled for Glass Contamination
Analysis Medication Safety / Pharmacovigilance
Aug 11, 2026 · Published in: FDA MedWatch
Alert: Tyenne Injection recall due to glass particles risk.
Deintensification Doubled But Still Lags in Overtreated Older Diabetics
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Low
Le P, Guo N, Misra-Hebert AD, et al.
Aug 10, 2026 · Published in: JAMA Internal Medicine
Exploring medication changes for older adults with diabetes.
How Clinicians Want Deprescribing Written Into Practice Guidelines
Analysis Guideline: Beers Criteria / Older Adults Hypothesis-generating Grade: Low
Langford AV, Liau SJ, Loh S, et al.
Aug 10, 2026 · Published in: Journal of General Internal Medicine
Enhancing deprescribing guidelines could improve care for older adults.
Marine-Derived Drugs in Alzheimer's: Modest, Inconsistent Cognitive Signals
Analysis Neurology / Neuropharmacology Hypothesis-generating Grade: Low
Song Z, Xie Y, Zhu H, et al.
Aug 10, 2026 · Published in: Therapeutic Advances in Neurological Disorders
Marine-derived drugs show potential but varied cognitive effects in Alzheimer's.
New CAR-T Therapy Shows Promise for Relapsed B-ALL
Analysis Oncology Pharmacy
Hu E, Johnson S, Abinsay T, et al.
Aug 10, 2026 · Published in: The Annals of Pharmacotherapy
Obecabtagene autoleucel shows promising results in tough-to-treat B-ALL cases.
GLP-1 Receptor Agonists Show No Excess Bowel Obstruction Risk
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate
Matsuo Y, Okada A, Sakamoto T, et al.
Aug 9, 2026 · Published in: Diabetes, Obesity & Metabolism
GLP-1 receptor agonists show no increased bowel obstruction risk compared to SGLT2 inhibitors.
5-ASA Delivers Deep Objective Remission, But Urgency Persists in UC
Analysis Clinical Practice Confirmatory Grade: Low
Reenaers C, Lambrecht G, Pouillon L, et al.
Aug 9, 2026 · Published in: Journal of Crohn's & Colitis
5-ASA shows strong remission rates but struggles with deep remission in UC.
Daratumumab plus anti-CD20 rescues refractory recurrent FSGS after transplant
Analysis Rheumatology / Immunology Hypothesis-generating Grade: Low
Leon J, Ducrocq E, Lafargue MC, et al.
Aug 9, 2026 · Published in: Kidney International Reports
Can dual antibody therapy offer a lifeline for transplant patients with recurrent FSGS?
Korea's Hospital Polypharmacy Program Cuts 90-Day Readmissions in Elders
Analysis Geriatrics / Geriatric Pharmacy Confirmatory Grade: Moderate
Aug 8, 2026 · Published in: Drugs & Aging
Polypharmacy management slashes readmission rates and costs for older adults.